Steven Lee, MD
Orthopaedic Surgery of the Spine · Walnut Creek, CANPI 1699725945
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $107,129 of the $115,626 with a category attached, or 92.7%. Medacta USA, Inc. accounts for 92.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $29,433 and has fallen 99.9% since, to $18 in 2025.
Across 41 payments — averaging $2820.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medacta USA, Inc.$107K
- Nvision Biomedical Technologies, Inc.$5K
- Cerapedics Inc.$3K
- Medtronic$153
- Vertex$18
Across 7 payments — averaging $18,071 each. An ownership or investment interest held by the physician or an immediate family member.
- 4web, Inc.$126K
What the payments were for
- Royalty or licence$107,12993%
- Consulting fees$5,1254%
- Speaking & faculty fees$5000%
- Travel & lodging$2,2702%
- Food & beverage$5250%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medacta USA, Inc. | 19 | $107,129 |
| Nvision Biomedical Technologies, Inc. | 6 | $5,463 |
| Cerapedics Inc. | 11 | $2,863 |
| Medtronic | 4 | $153 |
| Vertex | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MECTALIF$107,129
- I-FACTOR PEPTIDE ENHANCED BONE GRAFT$3,786
- Spine products$3,000
- Interbody$1,679
- Spine$784
- DIVERGENCE-L$103
How this compares
$115,626 in reported general payments places this provider in the 75th percentile of 288 orthopaedic surgery of the spine providers in California.
See all orthopaedic surgery of the spine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 266 | $1,824 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 53 | $955 |
| Celecoxib | 22 | $944 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 22 | $137 |
| Meloxicam | 37 | $130 |
| Tizanidine Hcl | 17 | $97 |
| Methylprednisolone | 17 | $82 |
| Tramadol Hcl | 29 | $78 |
| Baclofen | 12 | $47 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery of the spine in Walnut Creek
- Abid QureshiWalnut Creek$1.2M
- Hyun BaeSanta Monica$56.8M
- Choll KimSan Diego$4M
- Stacey BedermanOrange$3.7M
- Gregory Mundisla Jolla$3.3M
- Paul SlosarDaly City$3.1M
- Babak Barcohanavan Nuys$2.9M
- Neelakantan AnandLos Angeles$2.9M
- Sanjay KhuranaMarina del Rey$2.3M
- Neville AlleyneOceanside$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.